Bartlett & Co’s Sarepta Therapeutics SRPT Stock Holding History

Bartlett & Co’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3	Closed	–	–	1073
2021 Q1	$0	Hold	3	–	–	﹤0.01%	1162
2020 Q4	$1K	Buy	+3	New	+$445	﹤0.01%	1062

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bartlett & Co's SRPT Position: Q2 2021 in Review

Bartlett & Co sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 3 shares.

Bartlett & Co first reported a position in SRPT in Q4 2020 and held it in 2 quarters. The position peaked at $1K in Q4 2020. 330 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

Bartlett & Co reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
Bartlett & Co sold 3 Sarepta Therapeutics shares in Q2 2021.
Bartlett & Co first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 2 quarters.
Bartlett & Co's Sarepta Therapeutics position peaked at $1K in Q4 2020.
330 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on Bartlett & Co's 13F filing for Q2 2021, filed 19 Jul 2021.